Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018

  • ID: 4592433
  • Drug Pipelines
  • 243 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akcea Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Dr. Falk Pharma GmbH
  • Gemphire Therapeutics Inc
  • Kowa Co Ltd
  • NovaTarg Therapeutics Inc
  • MORE
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights:

This latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 18, 11, 25 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akcea Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Dr. Falk Pharma GmbH
  • Gemphire Therapeutics Inc
  • Kowa Co Ltd
  • NovaTarg Therapeutics Inc
  • MORE
Introduction

Non Alcoholic Fatty Liver Disease (NAFLD) - Overview

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Development

Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment

Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development

Non Alcoholic Fatty Liver Disease (NAFLD) - Drug Profiles

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects

Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products

Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Akcea Therapeutics Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ardelyx Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by AstraZeneca Plc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Betagenon AB, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by BioElectron Technology Corp, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Bird Rock Bio Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cadila Healthcare Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Can-Fite BioPharma Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Cerenis Therapeutics Holding SA, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Corcept Therapeutics Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by CymaBay Therapeutics Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corp, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eli Lilly and Co, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Enanta Pharmaceuticals Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Eternygen GmbH, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Evgen Pharma Plc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed Pharmaceuticals Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gemphire Therapeutics Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by HemoShear Therapeutics, LLC, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Global Co Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Immuron Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Inventiva, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kowa Co Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by MallInckrodt Plc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metacrine Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Mina Therapeutics Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NovaTarg Therapeutics Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by NuSirt Biopharma Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Pfizer Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Phenex Pharmaceuticals AG, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Renova Therapeutics Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Ritter Pharmaceuticals Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Sancilio & Company Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Theratechnologies Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Viking Therapeutics Inc, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2018 (Contd..1), H2 2018

Non Alcoholic Fatty Liver Disease (NAFLD) - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akcea Therapeutics Inc
  • Ardelyx Inc
  • AstraZeneca Plc
  • Betagenon AB
  • BioElectron Technology Corp
  • Bird Rock Bio Inc
  • Boehringer Ingelheim GmbH
  • Cadila Healthcare Ltd
  • Can-Fite BioPharma Ltd
  • Cerenis Therapeutics Holding SA
  • Corcept Therapeutics Inc
  • CymaBay Therapeutics Inc
  • Daewoong Pharmaceutical Co Ltd
  • Dr. Falk Pharma GmbH
  • DURECT Corp
  • Eli Lilly and Co
  • Enanta Pharmaceuticals Inc
  • Eternygen GmbH
  • Evgen Pharma Plc
  • Galmed Pharmaceuticals Ltd
  • Gemphire Therapeutics Inc
  • Gilead Sciences Inc
  • HemoShear Therapeutics, LLC
  • Huons Global Co Ltd
  • Immuron Ltd
  • Inventiva
  • Kowa Co Ltd
  • Kyorin Pharmaceutical Co Ltd
  • MallInckrodt Plc
  • Metacrine Inc
  • Mina Therapeutics Ltd
  • Novartis AG
  • NovaTarg Therapeutics Inc
  • NuSirt Biopharma Inc
  • Pfizer Inc
  • Phenex Pharmaceuticals AG
  • Renova Therapeutics Inc
  • Ritter Pharmaceuticals Inc
  • Sancilio & Company Inc
  • Shenzhen HighTide Biopharmaceutical Ltd
  • TaiwanJ Pharmaceuticals Co Ltd
  • TCM Biotech International Corp
  • Theratechnologies Inc
  • Viking Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll